- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
A Brexit Boost for German Pharma?
Research conducted by CPhI Worldwide, drawing from the CPhI Annual Report, ranks Germany as Europe’s preeminent pharma industry.
According to the report’s Pharma Index, Germany finished ahead of its European rivals in API manufacturing, competitiveness, innovation, finished product manufacturing, and growth potential, thus “consolidating its status as an elite pharmaceutical market.”
One of the most notable trends, the report states, is the sudden rise in anticipated growth potential for Germany in 2019/2020, increasing by 11% from 2018. The research’s authors attribute the shifting European outlook over the last couple of years to wider macro changes, as well as the continued strength of European pharma. Germany is perceived to be reaping a “Brexit boost” in its medium-term growth potential – with an equal drop in the UK scores directly correlating to the increases seen in Germany’s.
The full CPhI Pharma Market Index will be available later in the year as part of the CPhI 2019 Industry Report. This year’s CPhI Worldwide event will be held at Messe Frankfurt, Germany, November 5-7, 2019.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
